The dispute over Soliris patents between Samsung Bioepis and Alexion will be dealt with in the second trial. According to the pharmaceutical industry on the 19th, Alexion recently filed a lawsuit against Samsung Bioepis to cancel the trial decision. Alexion registered two Soliris patents. However, among the two patents, the composition patent expired in July 2015. The remaining patents are patents for use that expire in 2025. In June last year, Samsung Bioepis filed a request for invalidation of the patent for use. In February this year, Samsung Bioepis won the first trial.

Samsung Bioepis qualified for the release of the Soliris biosimilar by winning the first trial. However, there is a possibility tha